Published in J Virol on September 30, 2009
Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J Virol (2012) 1.05
Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells. PLoS Pathog (2015) 0.83
CAML does not modulate tetherin-mediated restriction of HIV-1 particle release. PLoS One (2010) 0.78
Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains. J Virol (2016) 0.76
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe (2008) 9.27
A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science (1988) 6.30
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72
An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe (2007) 4.17
Identification of a protein encoded by the vpu gene of HIV-1. Nature (1988) 4.05
HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog (2006) 3.97
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog (2009) 3.66
NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science (1997) 2.75
Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol (2009) 2.35
NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells. Clin Immunol (2000) 1.74
Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. Nature (1994) 1.71
Retracted Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu. Nat Med (2008) 1.63
Cell type-dependence for Vpu function. J Med Primatol (1994) 1.47
CAML is required for efficient EGF receptor recycling. Dev Cell (2003) 1.34
CAML is a p56Lck-interacting protein that is required for thymocyte development. Immunity (2005) 1.16
Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABA(A) receptors. Mol Cell Neurosci (2008) 1.05
Reciprocal modulatory interaction between human immunodeficiency virus type 1 Tat and transcription factor NFAT1. Mol Cell Biol (1999) 0.98
Major histocompatibility complex class II molecules promote human immunodeficiency virus type 1 assembly and budding to late endosomal/multivesicular body compartments. J Virol (2006) 0.98
CAML loss causes anaphase failure and chromosome missegregation. Cell Cycle (2009) 0.92
A hydrophobic domain of Ca2+-modulating cyclophilin ligand modulates calcium influx signaling in T lymphocytes. J Biol Chem (1996) 0.91
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med (2009) 6.18
A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med (2004) 4.07
Assessing the association of appropriateness of coronary revascularization and clinical outcomes for patients with stable coronary artery disease. J Am Coll Cardiol (2012) 3.45
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol (2004) 2.78
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med (2007) 2.50
Impact of patient and target-vessel characteristics on arterial and venous bypass graft patency: insight from a randomized trial. Circulation (2007) 2.39
LARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associated. Nucleic Acids Res (2008) 2.38
A randomized comparison of intraoperative indocyanine green angiography and transit-time flow measurement to detect technical errors in coronary bypass grafts. J Thorac Cardiovasc Surg (2006) 2.35
Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol (2009) 2.35
Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest (2003) 2.21
HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog (2007) 2.13
Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog (2010) 2.12
Ontario multidetector computed tomographic coronary angiography study: field evaluation of diagnostic accuracy. Arch Intern Med (2011) 1.97
Productive human immunodeficiency virus type 1 assembly takes place at the plasma membrane. J Virol (2007) 1.66
Formation of mobile chromatin-associated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest. PLoS Pathog (2010) 1.65
HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci (2007) 1.64
HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood (2009) 1.63
Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med (2007) 1.59
The impact of diabetic status on coronary artery bypass graft patency: insights from the radial artery patency study. Circulation (2008) 1.51
Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology (2007) 1.48
MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. FASEB J (2010) 1.39
Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from RAPS (Radial Artery Patency Study). J Am Coll Cardiol (2012) 1.34
Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. J Biol Chem (2003) 1.33
Assessment of the role of the central DNA flap in human immunodeficiency virus type 1 replication by using a single-cycle replication system. J Virol (2004) 1.19
Role of CD4 receptor down-regulation during HIV-1 infection. Curr HIV Res (2004) 1.10
HIV-1 Vpr induces the K48-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest. J Virol (2010) 1.08
Determinants of variations in coronary revascularization practices. CMAJ (2011) 1.08
Importin alpha3 interacts with HIV-1 integrase and contributes to HIV-1 nuclear import and replication. J Virol (2010) 1.07
Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase. Curr Opin Virol (2012) 1.06
HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface. Traffic (2011) 1.06
Quality of life after late invasive therapy for occluded arteries. N Engl J Med (2009) 1.06
Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J Virol (2012) 1.05
Design of a trans protease lentiviral packaging system that produces high titer virus. Retrovirology (2007) 1.05
Contribution of the C-terminal tri-lysine regions of human immunodeficiency virus type 1 integrase for efficient reverse transcription and viral DNA nuclear import. Retrovirology (2005) 1.04
A late role for the association of hnRNP A2 with the HIV-1 hnRNP A2 response elements in genomic RNA, Gag, and Vpr localization. J Biol Chem (2004) 1.01
Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. Virology (2007) 1.00
Major histocompatibility complex class II molecules promote human immunodeficiency virus type 1 assembly and budding to late endosomal/multivesicular body compartments. J Virol (2006) 0.98
Hypophosphorylation of poly(A) polymerase and increased polyadenylation activity are associated with human immunodeficiency virus type 1 Vpr expression. Virology (2002) 0.96
Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PLoS One (2010) 0.96
The evaluation of a formalized queue management system for coronary angiography waiting lists. Can J Cardiol (2005) 0.94
Recent advances in the understanding of HIV-1 Vpu accessory protein functions. Curr Drug Targets Immune Endocr Metabol Disord (2004) 0.94
Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. FASEB J (2011) 0.91
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med (2002) 0.90
HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain. FASEB J (2010) 0.90
Oral pathogens and allergic disease: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol (2006) 0.90
Naturally-occurring genetic variants in human DC-SIGN increase HIV-1 capture, cell-transfer and risk of mother-to-child transmission. PLoS One (2012) 0.89
Thrombus aspiration during primary percutaneous coronary intervention is associated with reduced myocardial edema, hemorrhage, microvascular obstruction and left ventricular remodeling. J Cardiovasc Magn Reson (2012) 0.88
Synthesis of unsymmetrical 3,4-diaryl-3-pyrrolin-2-ones utilizing pyrrole Weinreb amides. J Org Chem (2011) 0.88
CD4 dimers constitute the functional component required for T cell activation. J Immunol (2002) 0.87
Interactions between human immunodeficiency virus (HIV)-1 Vpr expression and innate immunity influence neurovirulence. Retrovirology (2011) 0.87
Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol (2006) 0.87
The tyrosine-based YXXØ targeting motif of murine leukemia virus envelope glycoprotein affects pathogenesis. Virology (2004) 0.86
Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex. Virus Res (2006) 0.86
Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J (2004) 0.86
Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae. Retrovirology (2004) 0.86
Association between disruption of CD4 receptor dimerization and increased human immunodeficiency virus type 1 entry. Retrovirology (2006) 0.84
Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr. J Biol Chem (2002) 0.83
The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents. Can J Cardiol (2007) 0.83
A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting. Can J Cardiol (2004) 0.83
Radial artery angiographic string sign: clinical consequences and the role of pharmacologic therapy. Ann Thorac Surg (2006) 0.83
Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients. J Clin Microbiol (2002) 0.82
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Am J Cardiol (2005) 0.81
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA (2002) 0.81
Risk stratification, management and outcomes of patients with non-ST elevation acute coronary syndrome: a Canadian teaching hospital perspective. Can J Cardiol (2003) 0.81
Predictors of normal coronary arteries at coronary angiography. Am Heart J (2013) 0.81
Extracellular human immunodeficiency virus type 1 viral protein R causes reductions in astrocytic ATP and glutathione levels compromising the antioxidant reservoir. Virus Res (2012) 0.81
Long-term safety and effectiveness of drug-eluting stents for the treatment of saphenous vein grafts disease: a population-based study. JACC Cardiovasc Interv (2011) 0.81
Cell context-dependent involvement of ATR in early stages of retroviral replication. Virology (2009) 0.81
Cardiovascular risk profiles and outcomes of Chinese living inside and outside China. Eur J Cardiovasc Prev Rehabil (2010) 0.80
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention. J Interv Cardiol (2003) 0.80
Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication. Retrovirology (2008) 0.79
One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. Can J Cardiol (2010) 0.79
Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. Am Heart J (2002) 0.79
Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. Am Heart J (2004) 0.79
Differential type 1 interferon-regulated gene expression in the brain during AIDS: interactions with viral diversity and neurovirulence. FASEB J (2013) 0.79
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation (2002) 0.79
Takotsubo cardiomyopathy and left ventricular outflow tract obstruction. J Interv Cardiol (2009) 0.79
Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Am Heart J (2007) 0.79
Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J Am Coll Cardiol (2003) 0.79
Modulation of allergic airway inflammation by the oral pathogen Porphyromonas gingivalis. Infect Immun (2010) 0.79
Viral protein R upregulates expression of ULBP2 on uninfected bystander cells during HIV-1 infection of primary CD4+ T lymphocytes. Virology (2013) 0.78
Clopidogrel in interventional cardiology: questions answered and questions remaining. Can J Cardiol (2002) 0.78